key: cord-0939519-ge0gfvrb
authors: Harris, Paul E.; Brasel, Trevor; Massey, Christopher; Herst, C. V.; Burkholz, Scott; Lloyd, Peter; Blankenberg, Tikoes; Bey, Thomas M.; Carback, Richard; Hodge, Thomas; Ciotlos, Serban; Wang, Lu; Comer, Jason E.; Rubsamen, Reid
title: A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques
date: 2021-04-26
journal: bioRxiv
DOI: 10.1101/2021.04.24.441228
sha: 73f3b231a60828250325d8c47fafdc9f41a4a3db
doc_id: 939519
cord_uid: ge0gfvrb

Background Persistent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has given rise to a COVID-19 pandemic. Several vaccines, evoking protective spike antibody responses, conceived in 2020, are being deployed in mass public health vaccination programs. Recent data suggests, however, that as sequence variation in the spike genome accumulates, some vaccines may lose efficacy. Methods Using a macaque model of SARS-CoV-2 infection, we tested the efficacy of a peptide-based vaccine targeting MHC Class I epitopes on the SARS-CoV-2 nucleocapsid protein. We administered biodegradable microspheres with synthetic peptides and adjuvants to rhesus macaques. Unvaccinated control and vaccinated macaques were challenged with 1 x 108 TCID50 units of SARS-CoV-2, followed by assessment of clinical symptoms, viral load, chest radiographs, sampling of peripheral blood and bronchoalveolar lavage (BAL) fluid for downstream analysis. Results Vaccinated animals were free of pneumonia-like infiltrates characteristic of SARS-CoV-2 infection and presented with lower viral loads relative to controls. Gene expression in cells collected from BAL samples of vaccinated macaques revealed a unique signature associated with enhanced development of adaptive immune responses relative to control macaques. Conclusions We demonstrate that a room temperature stable peptide vaccine based on known immunogenic HLA Class I bound CTL epitopes from the nucleocapsid protein can provide protection against SARS-CoV-2 infection in non-human primates. Graphical Abstract

6 of 43 of vaccine microsphere preparation in 1ml was used for each LN injection (two injections / dose / 197 animal) and 100mg of vaccine microspheres in a 5 ml volume was used for each IT administration. 198 Specifically, on Day -51 (51 days prior to virus challenge), two of the macaques (Figure 1 ) were 199 administered 2 mL of vaccine via LN injection (1 mL per node). Subsequent administration of the 200 vaccine occurred via the IT route (5 mL) only as described previously [42] . Remaining vaccine 201 doses, administered on Days -28 and -14, were delivered via IT only (5 mL per dose) to the rhesus 202 vaccination group. On , femoral vein peripheral 203 blood (8 mL) was collected from each animal into a BD Vacutainer® CPT TM Cell Preparation Tube 204 with Sodium Heparin (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and processed 205 to peripheral blood mononuclear cells (PBMCs) per manufacturer instructions. Collected PBMCs 206 were assessed for immunoreactivity via ELISPOT. In brief, ELISPOT assay plates (MabTech Inc., 207 Cincinnati, OH, USA) specific for the detection of primate IFN were used according to manufac-208 turer instructions. BAL cell concentrations were adjusted to 1 x 10 5 cells per mL in a complete growth 209 medium. Diluted BAL cells were dispensed (100µL/well) into a 96-well plate after which 100µL of 210 complete growth medium (CGM, negative control), Concanavalin A in CGM at 10 µg per well (pos-211 itive control), and various concentrations of specific (i.e., immunizing) and non-specific peptides 212 (Supplemental data, Table S1B) were added. Peptides used for immunization were added to wells 213 at a concentration of 50 µM. All samples were assayed in duplicate. Plates were incubated at 214 37°C/5% CO2 for 20-22 hours after which plates were thoroughly washed. Conjugated detection 215 antibody was then added and incubated followed by additional washing. Wells were developed using TMB as a substrate. Counts were performed at Cellular Technology Corporation (Shaker 225 Heights, OH, USA) using an Immunospot Analyzer and all well images were quality-controlled on 226 site. All spot-forming cell counts reported are the result of averaging counts from the duplicate 227 50µM immunization-specific peptide wells.

Virus challenge 230 On Day 0, macaques were administered 1-5 ×10 8 TCID50 SARS-CoV-2 (USA_WA1/2020) via com-231 bined mucosal atomization (1 mL as delivered using a MAD Nasal TM Intranasal Mucosal Atomiza-232 tion Device per manufacturer instructions) and intratracheal instillation (4 mL). Intratracheal instil-233 lations were performed as described above for delivery of the vaccine. The virus suspension was 234 prepared on the day of challenge from frozen seed stock (kindly provided by Dr. Chien-Te [Kent] 235 Tseng at UTMB) initially generated (one passage) in Vero C1008 (E6) cells (BEI Resources, 236 Lot 3956593) from original material provided by the Centers for Disease Control and Prevention in 237 January 2020. Next-generation sequencing confirmed a 100% consensus sequence-level match to the 238 original patient specimen (GenBank accession MN985325.1).

Post-challenge monitoring and chest radiography 241 Animals were monitored and scored twice daily for clinical signs of disease including alterations in 242 activity/appearance (i.e., hunched posture), food consumption/waste output, and were scored 243 based on general appearance, activity, food consumption, and outward changes in breathing pat-244 terns. Prospectively defined criteria that required immediate euthanasia included severe dyspnea 245 and/or agonal breathing and prostate posture/reluctance to move when stimulated. No animals met 246 endpoint criteria during the study. Ventrolateral chest radiography was performed on the days in-247 dicated ( Figure 1 ) using a portable GE AMX-4+ computed radiography system per manufacturer 248 instruction. DICOM data files were independently evaluated by two independent investigators 249 blinded to group assignment with large animal imaging experience via a four-pattern approach 250 (analyses of consolidation, interstitial areas, nodules or masses, and atelectasis).

Biosampling 253 Blood, nasal cavity samples, and BAL fluid were collected at the indicated times ( Figure 1 ). Femoral 254 vein peripheral blood was collected via Vacutainer® into standard collection tubes containing eth-255 ylenediaminetetraacetic acid (EDTA). Hematology was performed on EDTA blood using the Abaxis 256 VETSCAN® HM5 Hematology Analyzer (Abaxis, Inc., Union City, CA, USA). Nasal cavity samples, 257 collected using sterile cotton-tipped medical swabs, were placed into 0.5 mL sterile phosphate-buff-258 ered saline (PBS) for viral load analysis. For BAL fluid collection, animals were sedated as previ-259 ously described and placed in ventral recumbency. The trachea was visualized and cannulated by 260 an appropriately sized rubber feeding tube. Following the placement of the feeding tube, 20mL of 261 sterile PBS was introduced into the lung and recovered manually through the feeding tube via sy-262 ringe. This was repeated for a total of 40mL per animal. The total collected volume from each animal 263 (10-30mL) was pooled and centrifuged under ambient conditions (10 min at 500 x g) after which the Coralville, IA, USA) was labeled at the 5'-end with fluorophore 9-carboxyfluoroescein (6-FAM) and 284 included an internal quencher (ZEN) and a 3'-end quencher (IowaBlackFQ, IABkFQ). Master Mix 285 was prepared by combining forward primer (250 nM, 5'-ACAGGTACGTTAATAGTTAATAGCGT- tem. Thermocycling conditions were as follows:

Step 1, 1 cycle, 50°C for 10 minutes;

Step 2, 1 cycle, 292 95°C for 10 minutes; Steps 3-5, 45 cycles, 95°C for 10 seconds, 60°C for 30 seconds, single read. Neg-293 ative controls included reaction mixtures without RNA. For quantification purposes, viral RNA ex-294 tracted from the virus seed stock with a known TCID50/mL titer was used. All qRT-PCR results are 295 expressed as TCID50/mL equivalents. Macaque C75243 (cynomolgus) was not included in this study. BAL samples were processed to RNA as described above for qRT-PCR analysis. RNA quantity and 300 quality were assessed using a NanoDrop TM Lite Spectrophotometer (ThermoFisher Scientific, Wal-301 tham, MA, USA). Samples, normalized to 20ng/L, were analyzed by NanoString Technologies (Se-302 attle, WA, USA) using the nCounter® SPRINT™ Profiler gene expression profiling using the Non-303 Human Primate Immunology V2 Panel containing 754 genes that encompass 17 immune-related 304 signaling pathways with isoform coverage for both Macaca mulatta and Macaca fascicularis. Probe 305 sets that did not cover both Macaca species were eliminated resulting in a probe set of 730 genes. 306 Raw gene expression data sets received from NanoString Technologies were processed to remove 307 background signals and normalized using the nSolver TM V.3.0 digital analyzer software. Back-308 ground signal correction was accomplished by subtracting the NanoString negative control genes. Descriptive statistics were performed using Microsoft Excel. Hypothesis testing was performed by 321 considering the null hypothesis of the absence of an association between the compared variables. 322 The statistical strength of associations of continuous data was tested using Students t-testing. Qlu-323 core Omics Explorer 3.5 (Qlucore), Metascape (Metascape.org) was used to identify the discriminat-324 ing variables within the NanoString gene expression data sets from BAL sample analysis that were 325 most significantly different between vaccinated and control subjects. The identification of signifi-326 cantly differential variables between the two groups was performed by fitting a linear model for 327 each variable. The set of genes (87 variable genes out of a total of 730 genes) was identified using a 328 p-value of 0.05, at least a three-fold change, and a q-value cutoff of 0.1. P-values were adjusted for 329 multiple testing using the Benjamini-Hochberg method [44] . Gene expression data were scaled to a 330 mean = 0 and a variance = 1 before clustering. Hierarchical clustering of gene expression in BAL was 331 performed using a supervised weighted average linkage two comparisons approach. The metric 332 used in scaling dendrogram arms was Pearson's correlation coefficient. Figure S2 ). Overall, the number of white blood cells was significantly increased in control clearance rate from Days 2 through 10 was 4-5 fold higher in two of the four vaccinated macaques 382 (RA1693 and RA3797) relative to the unvaccinated controls (Supplemental data, Figure S3 ).

Macaque chest radiography 385 SARS-CoV-2 challenge in unvaccinated controls resulted in mild-to-moderate lung abnormalities, 386 similar to those previously reported for macaques [6, 15, 16, 20, [45] [46] [47] [48] . These were predominantly lim-387 ited to the caudal lung relative to baseline images, peaked 3-5 days post-challenge, and were quali-388 tatively characteristic of subclinical or mild-to-moderate human COVID-19 (e.g., ground-glass opac-389 ities with or without reticulation, paving, silhouetting, and/or linear opacities). The mild to moder-390 ate interstitial pneumonitis seen on the ventrolateral chest radiographs of unvaccinated subjects are 391 consistent with focal infiltrates representing a complex of interstitial macrophages, neutrophils, and 392 plasmacytoid dendritic cells [49] . Abnormalities in control animals resolved by Days 10-21. In con-393 trast, vaccinated macaques lacked the appearance of ground-glass opacities in all regions of the lung 394 throughout the study period ( Figure 4 and Supplemental data, Figures S4-S9) . We did observe, 395 however, modest bilateral increases in reticulation in vaccinated macaques on Days 3-5, but these 396 abnormalities also resolved by Day 10-21. Bronchoalveolar lavage has been reported to affect com-397 puterized tomography X-ray results in healthy rhesus macaques [50] . In our study, however, the 398 pattern of reported changes in vaccinated (i.e., healthy) animals on which BAL was performed was 399 more similar to increases in reticulation versus the patchy consolidations observed in the unvac-400 cinated controls. In contrast, vaccinated macaques (right columns C and D) lacked similar abnormalities. White ar-417 rows indicate areas of mild to moderate pulmonary infiltrates seen as ground glass consolidations. 418 Analysis of gene expression patterns in BAL cells 421 We identified a set of 87 genes in BAL samples collected 5-7 days post-challenge from control ani-422 mals with statistically significant differential expression (as measured from changes in accumula-423 tion of their specific transcripts) versus BAL samples collected from vaccinated animals during the 424 same time points (Figures 5 and 6) . We selected to focus on the Day 5 and Day 7 samples to capture 425 a possible peak of adaptive immune responses to SARS-CoV-2 challenge as suggested by previous 426 reports [51, 52] . Several of the identified differentially regulated genes were of particular interest in 427 the context of adaptive viral T cell immunity (Tables 1 and 2) . Several differentially regulated im-428 mune response genes laying outside the main window of interest (i.e., Day 5 alone, Day 7 alone, or 429 Day 10 alone) were also identified (Tables 1 and 2 and Supplemental data, Figure S10 ). sess the possible effects and efficacy of our vaccination procedure and formulation, we compared 515 the expression of 60 genes previously reported to be up-regulated, not by antigenic stimulation, but 516 by adjuvants alone [59] [60] [61] [62] [63] . We found 30 out of 60 genes examined to be significantly (p<0.05) and 517 differentially (> 2 fold) regulated in BAL cells obtained from vaccinated but unchallenged macaques 518 (Day -7) relative to samples from unchallenged control animals (Day-1) (Supplemental data, Figure   519 S13). This pattern suggests that BAL-associated cells from vaccinated animals were stimulated by 520 the adjuvants in the vaccine formulation. As a further measure of vaccination efficiency, we meas-521 ured BAL immunoreactivity to the peptides via ELISPOT prior to SARS-CoV-2 challenge (Supple-522 mental data, Figure S14 ). We observed modest immunoreactivity to one of the six CTL peptides 523 (LL9) in 3 out of the 4 vaccinated pre-challenge macaques. We did not detect immunoreactivity to 524 the peptide antigens using samples of peripheral blood mononuclear cells (data not shown). x-rays as "ground-glass like consolidations", but few changes associate with human SARS COV-2 533 infection such as loss of appetite, respiratory distress, vomiting and/or diarrhea. We observed that 534 the kinetics of change in viral loads observed in control rhesus macaques were similar to those pre-535 viously reported [11] . Additionally, the lung tissue abnormalities revealed by chest radiography 536 were similar in the kinetics of progression and depth to previous reports [6, 15, 16, 20, [45] [46] [47] [48] IFNα2 genes in BAL cells recovered from vaccinated subjects relative to their unvaccinated controls. 566 The observation perhaps reflects the decreased viral loads found in vaccinated NHP subjects [5] . antibodies that promote disease have been described and categorized as ADE [67] or VAERD, such 570 as that described in MERS-CoV or RSV patients [68] [69] [70] . Since our vaccine only delivered low molec-571 ular weight nonameric synthetic peptides, unconjugated to any carrier, we did not expect to gener- aging. In particular, note lack of focal infiltrates or consolidations.

et 684 al. An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 685 challenge in rhesus macaques

Replication of SARS coronavirus administered into the 688 respiratory tract of African Green, rhesus and cynomolgus monkeys

Correlates of protection against SARS-CoV-2 in rhesus 692 macaques

Single-shot Ad26 vaccine protects against SARS-CoV-695 2 in rhesus macaques

Comparison of the immunogenicity & protective efficacy of various SARS-698

CoV-2 vaccine candidates in non-human primates

Respiratory disease and 702 virus shedding in rhesus macaques inoculated with SARS-CoV-2. bioRxiv 2020

Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in Rhesus 706 macaques

Responses to acute infection with SARS

CoV-2 in the lungs of rhesus macaques, baboons and marmosets

SARS-CoV-2 in Nonhuman Primates

Development of an inactivated vaccine candidate for SARS-CoV-2

NVX-CoV2373 vaccine protects cynomolgus 735 macaque upper and lower airways against SARS-CoV-2 challenge

A Thermostable mRNA Vaccine against COVID-19

Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent 742 Protection against SARS-CoV-2

DNA vaccine protection against SARS-CoV-2 in 745 rhesus macaques

Long-lived memory T lymphocyte responses against SARS coronavirus nucleocapsid protein 748 in SARS-recovered patients

Broad and strong memory CD4(+) and CD8(+) T cells induced by 751 SARS-CoV-2 in UK convalescent individuals following COVID-19

Genetic Variation and Evolution of the 768 2019 Novel Coronavirus

The nucleoprotein is required for efficient coronavirus 771 genome replication

NetMHCpan-4.0: 776 Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and 777 Peptide Binding Affinity Data

780 A complete sequence and comparative analysis of a SARS-associated virus

Sequence-based prediction of SARS

CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies 785 immunogenic T cell epitopes

Peptide-binding motifs associated with MHC molecules common in

Chinese rhesus macaques are analogous to those of human HLA supertypes and include

An Approach for a Synthetic CTL Vaccine Design against Zika Flavivirus 792

Using Class I and Class II Epitopes Identified by Computer Modeling. Front Immunol

Combined TLR4 and TLR9 858 agonists induce distinct phenotypic changes in innate immunity in vitro and in vivo

Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-862 kappaB, ERK and p38 MAPK signal pathways

Cellular events of acute, 866 resolving or progressive COVID-19 in SARS-CoV-2 infected non-human primates

Differential HLA gene 869 expression in measles vaccine seropositive and seronegative subjects: a pilot study

Early differences in cytokine production distinguish severity of 873 COVID-19

Antibody-dependent enhancement of severe dengue disease in humans

Immunogenicity and safety of a recombinant adenovirus type-5-899 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-900 blind, placebo-controlled, phase 2 trial

Safety and immunogenicity of the ChAdOx1 904 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, 905 randomised controlled trial

Exploiting albumin as a mucosal vaccine chaperone for robust generation of lung-908 resident memory T cells

/AZD1222 vaccination reduces shedding of SARS-CoV-2 D614G in rhesus macaques. 913 bioRxiv 2021

Predicting population 915 coverage of T-cell epitope-based diagnostics and vaccines

Genomic evolution of MHC class I region in primates

Day 7 (middle panel), and Day 1007 10 (right panel). 5-and 7-days post SARS-CoV-2 challenge. Heatmap shows significantly (p<0.05) 1008 up-regulated (red) transcripts and down-regulated (green) transcripts from a total of 730 genes an-1009 alyzed using the NanoString Non-Human Primate Immunology V2 Panel

Intratracheal vaccination with the adjuvanted micro-1014 sphere peptide vaccine did not promote the expression of Th2 type interleukin cytokine transcripts 1015 in collected BAL samples relative to levels measured in control macaques. BAL cell gene expres-1016 sion (shown as scaled counts on the y-axis) of cytokines associated with Th2 T cell responses were 1017 plotted by study day (x-axis) for each animal

No statistically significant differences between control and vaccinated macaques were found

Intratracheal vaccination with the adjuvanted microsphere pep-1023 tide vaccine did not promote the expression of Th2 type interleukin cytokine transcripts in col-1024 lected BAL samples relative to levels measured in control macaques. BAL cell gene expression 1025 (shown as scaled counts on the y-axis) of cytokines associated with Th2 T cell responses were plot-1026 ted by study day (x-axis) for each animal prior to and following the SARS-CoV-2 challenge

Gene expression analysis identified differentially regulated 1035 genes in BAL samples obtained on Day -1 from control animals and Day -7 from vaccinated ma-1036 caques. Heatmap shows significant (p <0.05) differential expression of a series of genes that had 1037 previously been identified (see main text) as being regulated by adjuvants alone

Macaque RA 3830 was not sampled on day -1

Immunoreactivity of BAL-associated cells from vac-1044 cinated macaques to immunizing peptides prior to SARS-CoV-2 challenge. Dates shown are assay 1045 date rather than sampling date. Concanavlin A was used as a positive control. Notes: 1. + Indicates positive in-vitro assays for MHC binding and/or T-cell recognition

Supplemental Table S1B

Rhesus Mamu MHC Class I coverage -predicted binding NHP Subject R1693 1 R1716 R3689 R3797

Notes: 1. A typical rhesus MHC haplotype may contain two or three expressed Mamu-A genes, and up to nineteen 1058 distinct Mamu-B-like loci[79], 2. Mamu MHC in italics are predicted to bind based on HLA homology and in-vitro 1059 analysis